The Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorisation to Autolus ...

LONDON, April 23, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation ...

View Our Latest Report on Autolus Therapeutics Autolus Therapeutics Stock Up 4.5 % AUTL opened at $1.39 on Tuesday. The stock has a market capitalization of $369.87 million, a price-to-earnings ...

Autolus Therapeutics plc, a biopharmaceutical company focused on next-generation programmed T cell therapies, has announced the upcoming release of its first quarter 2025 financial results and ...

Autolus Therapeutics (AUTL) confirmed that the U.K. Medicines and Healthcare products Regulatory Agency has granted ...

Autolus Therapeutics plc (AUTL)’s share was trading at $3.20 as of Dec 3rd. Autolus Therapeutics is a biopharmaceutical company focused on developing innovative CAR-T cell therapies for the ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) late Friday announced it has granted a conditional ...

Autolus Therapeutics plc announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorisation for AUCATZYL (obecabtagene autoleucel ...

The new conditional marketing authorization was granted on April 25 to Autolus Therapeutics (AUTL), the MHRA noted. Published first on TheFly – the ultimate source for real-time, market-moving ...

Autolus Therapeutics, a UCL spinout company, has received authorisation from the UK Medicines and Healthcare products ...

Autolus Therapeutics (AUTL) confirmed that the U.K. Medicines and Healthcare products Regulatory Agency has granted conditional marketing authorization for AUCATZYL for the treatment of adult ...

A replay of the webcast of the R&D investor event is available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at ...